MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

Prothena Corp PLC

Abierto

SectorSalud

9.69 1.04

Resumen

Variación precio

24h

Actual

Mínimo

9.23

Máximo

9.8

Métricas clave

By Trading Economics

Ingresos

1M

-58M

Ventas

1.2M

2.1M

BPA

-1.08

Margen de beneficio

-2,729.911

Empleados

163

EBITDA

1.6M

-65M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+465.49% upside

Dividendos

By Dow Jones

Próximas Ganancias

7 may 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-264M

501M

Apertura anterior

8.65

Cierre anterior

9.69

Puntuación técnica

By Trading Central

Confianza

Bullish Evidence

Prothena Corp PLC Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

28 may 2024, 22:51 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Bristol Myers Squibb Adds to Neurodegenerative Treatment Investments -- Market Talk

Comparación entre iguales

Cambio de precio

Prothena Corp PLC Esperado

Precio Objetivo

By TipRanks

465.49% repunte

Estimación a 12 meses

Media 54.57 USD  465.49%

Máximo 110 USD

Mínimo 20 USD

De acuerdo con 8 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Prothena Corp PLC Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

8 ratings

6

Comprar

2

Mantener

0

Vender

Puntuación técnica

By Trading Central

9.585 / 10.07Soporte y Resistencia

Corto Plazo

Bullish Evidence

Medio plazo

Strong Bearish Evidence

Largo Plazo

Weak Bearish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Prothena Corp PLC

Prothena Corporation PLC is a late-stage clinical company. The Company is engaged in the protein dysregulation and a pipeline of therapeutics for devastating neurodegenerative and rare peripheral amyloid diseases. It is advancing a pipeline of therapeutic candidates around neurological dysfunction and the biology of misfolded proteins. The Company's clinical pipeline of antibody-based product candidates targets a range of indications, including Birtamimab for the treatment of amyloid light-chain (AL) amyloidosis; prasinezumab for the treatment of Parkinson’s disease and other related synucleinopathies; and PRX004, for the treatment of Transthyretin amyloidosis (ATTR). The Company's pipeline also includes late-preclinical-stage programs targeting proteins implicated in neurological diseases including tau and amyloid beta (Aß) for the treatment of Alzheimer’s disease and other neurodegenerative disorders, and TDP-43 for the treatment of amyotrophic lateral sclerosis.